Clinical trials: System Sclerosis
Multiple Sclerosis
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting
The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting.
- Trial name
- NCT06261541
- Testing
- ABLE Exoskeleton
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- ABLE Human Motion S.L.
Stroke, Multiple Sclerosis
Quality of Life Assessment Between Stroke and Multiple Sclerosis Patients of the Same Age Range
The purpose of this study is to investigate the physical, psychological, social and functional aspects of life in relatively young people suffering from vascular stroke and in people diagnosed with multiple sclerosis of the same…
- Conditions
- Stroke, Multiple Sclerosis, Quality of Life, Depression
- Trial name
- QoLSMS (NCT04758494)
- Testing
- Questionnaire
- Where
- Greece
- Volunteers
- 172 people
- Sponsor
- Hellenic Red Cross Hospital
Multiple Sclerosis
B Cell Differentiation in MS
Interventional study with minimal risks and constraints, prospective, monocentric.
- Trial name
- ABCD-SEP (NCT03744351)
- Testing
- Biological Samples
- Where
- France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Multiple Sclerosis
Effectiveness of the EXOPULSE Mollii Ⓡ Suit in Patients With Multiple Sclerosis
Abstract: Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system with unknown etiology, causing a variety of symptoms including impaired balance, coordination, and…
- Trial name
- NCT06384729
- Testing
- EXOPULSE Mollii Ⓡ
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Universidad Europea de Madrid
Relapsing-Remitting Multiple Sclerosis
CLARITY Extension Study
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY).
- Trial name
- NCT00641537
- Testing
- Cladribine
- Where
- 116 sites in United States, Australia and 29 more
- Volunteers
- 867 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).
In this study the investigators wish to test the hypothesis that treatment with Lemtrada is associated with alterations in immune homeostasis in favor of multiple regulatory leukocyte populations which persist long after…
- Trial name
- NCT03647722
- Testing
- Assessment of leukocyte function.
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- University of Southern California
Scars, Scleroderma
Laser Treatment for the Improvement of Scars and Scleroderma
In this study, the investigators seek to evaluate the effects of a laser treatment on the redistribution/regeneration of collagen on the clinical, microscopic, and molecular profiles of hypertrophic scars and scleroderma.
- Trial name
- NCT04567537
- Testing
- Laser Treatment
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Multiple Sclerosis, Magnetic Resonance Imaging
Risk Factors in Early Multiple Sclerosis
The central hypothesis of this protocol is that it is possible, using First Degree Relatives (FDRs) of patients with Multiple Sclerosis (MS) and assessing a variety of both known and unknown risk factors for MS, to define a risk…
- Conditions
- Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome
- Trial name
- RISEMS (NCT03586986)
- Testing
- Brain MRI
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.
- Trial name
- NCT05298670
- Testing
- MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- German University in Cairo
Relapsing-Remitting Multiple Sclerosis
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
The primary objective of the study is to evaluate relapse activity, as measured by the proportion of participants relapsed at 12 months, in participants with relapsing-remitting multiple sclerosis (RRMS) who transition from…
- Trial name
- STRATEGY (NCT02159573)
- Testing
- natalizumab, dimethyl fumarate
- Where
- 43 sites in United States
- Volunteers
- 530 people
- Sponsor
- Biogen
Multiple Sclerosis
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
The planned study will be a prospective, non-interventional, observational cohort study using the structure of a registry. Medication usage behavior will be observed for 6 months, while documentation behavior on the wellness…
- Trial name
- PROmyBETAapp (NCT03134573)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect auto-injector, myBETAapp
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Bayer
Progressive Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis
The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs and the…
- Trial name
- VASOSEP (NCT02580669)
- Testing
- Neuropsychological assessment, Neurologic consultation, MRIs (with vasoreactivity testing)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Amyotrophic Lateral Sclerosis
Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis
The alteration of iron metabolism is reported in animal models of amyotrophic lateral sclerosis (ALS) as well as in sporadic and genetic forms (SOD1 and C9orf72) of ALS.
- Trial name
- FAIR-ALS II (NCT03293069)
- Testing
- Deferiprone
- Where
- 15 sites in France
- Volunteers
- 372 people
- Sponsor
- University Hospital, Lille
Relapsing Remitting Multiple Sclerosis
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab.
- Trial name
- TOPAZ (NCT02255656)
- Testing
- alemtuzumab GZ402673
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 1,062 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Complementary and Alternative Care in Multiple Sclerosis
This is a prospective, observational study designed to describe disease progression, symptom change, quality of life, diet and lifestyle habits, and frequency of adverse events among patients with multiple sclerosis (MS) who use…
- Trial name
- CAM Care in MS (NCT01703429)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bastyr University
Progressive Multiple Sclerosis (PMS)
The Effects of a 12-week In-phase Bilateral Exercise Programme on the Corticospinal Plasticity in People With Progressive Multiple Sclerosis
This study investigates whether a structured exercise program using coordinated movements of both arms can improve brain and motor function in people with Progressive Multiple Sclerosis (MS).
- Trial name
- NCT07548242
- Testing
- In-Phase Bilateral Upper Limb Exercise Program
- Where
- Cyprus
- Volunteers
- 5 people
- Sponsor
- Marinos Chatzikonstantinou
Multiple Sclerosis, Internuclear Ophthalmoplegia
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Primary fatigue represents a major cause of disability in patients with multiple sclerosis (MS), being reported in about 90% of cases.
- Conditions
- Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
- Trial name
- NCT02391961
- Testing
- Dalfampridine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS
This study evaluates the effects of sustained-release oral dalfampridine in the treatment of upper limb deficits in people with multiple sclerosis (MS).
- Trial name
- NCT02259361
- Testing
- Sustained-release oral dalfampridine
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Multiple Sclerosis
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
- Trial name
- ZENITH (NCT07224373)
- Testing
- AZD0120 - Regimen 1, AZD0120 - Regimen 2
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
- Trial name
- HERMOSA-2 (NCT07304154)
- Testing
- KITE-363, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 57 people
- Sponsor
- Kite, A Gilead Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.